You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森製藥(3692.HK):上半年總收入74.34億元同比增長14.3%,創新藥收入佔比82.7%
格隆匯 08-18 18:26

格隆匯8月18日丨翰森製藥(3692.HK)公佈業績顯示,2025年上半年實現總收入約74.34億元人民幣(單位下同),同比增長約14.3%;溢利約31.35億元,同比增長約15.0%。每股基本盈利約0.53元,同比增長約14.8%,派發中期股息每股23.16港仙,彰顯了公司良好的盈利能力及對股東的豐厚回報。

得益於創新產品持續放量及全球合作穩步推進,2025上半年,翰森製藥創新藥與合作產品銷售收入約61.45億元,同比增長約22.1%,佔總收入比例上升至82.7%。

根據財報,2025上半年公司經營活動淨現金流入36.05億元,於2025年6月30日擁有現金及銀行存款271.04億元。穩健的財務表現及強大的現金流,為支持公司未來持續創新研發投入奠定堅實基礎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account